title: Effects of famotidine, mosapride and tandospirone for treatment of functional dyspepsia.
abstract: BACKGROUND
  An effective therapeutic strategy for functional dyspepsia (FD) has not been well-established.
  
  
  OBJECTIVE
  We investigated and compared the therapeutic effects of famotidine, mosapride and tandospirone for the control of dyspeptic symptoms.
  
  
  METHODS
  Fully examined FD patients of outpatient clinics at seven different medical centres were enrolled in the study. They were randomly assigned to three groups based on the type of drug administered: famotidine, mosapride and tandospirone. The effects of treatment over 4 weeks were assessed by visual analogue scales.
  
  
  RESULTS
  All of the drugs showed beneficial effects, although famotidine was the most effective for symptom relief, which was significantly greater than tandospirone, while the effect of mosapride was similar to that of famotidine. No subtype of FD showed a better response to a particular type of drug.
  
  
  CONCLUSIONS
  For the treatment of FD, famotidine demonstrated the best therapeutic effect, followed by mosapride, while that of tandospirone was significantly lower.
authors.affiliation: Department of Gastroenterology and Hepatology, Shimane University School of Medicine, Izumo-shi, Shimane, Japan. kinosita@med.shimane-u.ac.jp
authors.forename: Y
authors.initials: Y
authors.lastname: Kinoshita
authors.forename: T
authors.initials: T
authors.lastname: Hashimoto
authors.forename: A
authors.initials: A
authors.lastname: Kawamura
authors.forename: M
authors.initials: M
authors.lastname: Yuki
authors.forename: K
authors.initials: K
authors.lastname: Amano
authors.forename: H
authors.initials: H
authors.lastname: Sato
authors.forename: K
authors.initials: K
authors.lastname: Adachi
authors.forename: S
authors.initials: S
authors.lastname: Sato
authors.forename: N
authors.initials: N
authors.lastname: Oshima
authors.forename: T
authors.initials: T
authors.lastname: Takashima
authors.forename: N
authors.initials: N
authors.lastname: Kitajima
authors.forename: K
authors.initials: K
authors.lastname: Abe
authors.forename: H
authors.initials: H
authors.lastname: Suetsugu
mesh_terms: D014151:Anti-Anxiety Agents / Q000627:therapeutic use; D000897:Anti-Ulcer Agents / Q000627:therapeutic use*; D001549:Benzamides / Q000627:therapeutic use*; D004415:Dyspepsia / Q000188:drug therapy*; D015738:Famotidine / Q000627:therapeutic use*; D005260:Female; D005765:Gastrointestinal Agents / Q000627:therapeutic use*; D006635:Histamine H2 Antagonists / Q000627:therapeutic use; D006801:Humans; D054833:Isoindoles; D008297:Male; D008875:Middle Aged; D009025:Morpholines / Q000627:therapeutic use*; D010879:Piperazines / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D014151:Anti-Anxiety Agents; D000897:Anti-Ulcer Agents; D001549:Benzamides; D005765:Gastrointestinal Agents; D006635:Histamine H2 Antagonists; D054833:Isoindoles; D009025:Morpholines; D010879:Piperazines; D011743:Pyrimidines; C055267:tandospirone; D015738:Famotidine; C062720:mosapride